# An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

> **NCT04586244** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 30 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** retifanlimab
- **DRUG:** epacadostat
- **DRUG:** INCAGN02385
- **DRUG:** INCAGN02390

## Key facts

- **NCT ID:** NCT04586244
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-14
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-01-29
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Business Decision. No safety concerns contributed to this decision.
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04586244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04586244, "An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04586244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*